The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Postdoctoral Program for Innovative Talents (BX20250256)
- National Natural Science Foundation of China (82473460)
- National Natural Science Foundation of China (82303718)
This publication has 52 references indexed in Scilit:
- Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBECLung Cancer, 2025
- Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic AdenocarcinomaDrugs, 2025
- Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRASG12D protein to cancer-associated fibroblastsMolecular Therapy, 2025
- APOBEC3C‐mediated NF‐κB activation enhances clear cell renal cell carcinoma progressionMolecular Oncology, 2024
- Constructing an APOBEC-related gene signature with predictive value in the overall survival and therapeutic sensitivity in lung adenocarcinomaHeliyon, 2023
- Estimated Projection of US Cancer Incidence and Death to 2040JAMA Network Open, 2021
- Looking to Long-term Survivors for Improved Pancreatic Cancer TreatmentJAMA, 2020
- Molecular origins of APOBEC-associated mutations in cancerDNA Repair, 2020
- Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)Archives of Pharmacal Research, 2019
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small MoleculesCell, 2013